Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Other solid neoplasm 3Head & Neck 2Gynecologic 2Genitourinary 2Gastrointestinal 2Dermatologic 2Sarcoma 1Breast 1

Conditions

Advanced Solid Tumor 6Solid Tumors 3Solid Tumor 3Mesothelioma 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumor, Adult 2Melanoma 2Cholangiocarcinoma 2Advanced Solid Tumors 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Refractory or Recurrent Solid Tumor 1Neoplasms, Unknown Primary 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Locally Advanced or Metastatic Solid Tumors 1Kidney Neoplasms 1Esophageal Neoplasms 1DMMR Colorectal Cancer 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Pemetrexed 40Cisplatin 35pembrolizumab 21Nivolumab 17Carboplatin 16Ipilimumab 13Gemcitabine 10Cyclophosphamide 9fludarabine 6durvalumab 6Bevacizumab 6Radiotherapy, Intensity-Modulated 4LMB-100 4Drug Therapy 4Dexamethasone 4tremelimumab 3tazemetostat 3spartalizumab 3olaparib 3niraparib 3atezolizumab 3anetumab ravtansine 3amatuximab 3Vinorelbine 3Paclitaxel 3Oxaliplatin 3Imatinib Mesylate 3Fluorouracil 3Cerebral Decortication 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Mesothelioma × spartalizumab × Other solid neoplasm × Clear all
NCT04802876 2025-03-21

ACROPOLI

SOLTI Breast Cancer Research Group

Phase 2 Active not recruiting
184 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04672434 2024-12-09

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

Symphogen A/S

Phase 1 Completed
48 enrolled
GastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Esophageal Neoplasms, Mesothelioma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02460224 2022-02-10

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Novartis

Phase 1/2 Completed
490 enrolled 77 charts
DermatologicGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Melanoma, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡